Role of the blood-brain barrier in Alzheimer's disease;La barrière hématoencéphalique une nouvelle cible thérapeutique dans la maladie d'Alzheimer?

Medecine/Sciences

Volumn 27, Issue 11, 2011, Pages 987-992

  Gosselet, Fabien ^a   Candela, Pietra ^a   Cecchelli, Roméo ^a   Fenart, Laurence ^a  

^a UNIVERSITÉ D'ARTOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; BRAIN; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PERICYTE; PHYSIOLOGY; PROTEIN TRANSPORT; VASCULARIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; PERICYTES; PROTEIN TRANSPORT;

EID: 83455225221     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20112711015     Document Type: Article

References (32)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66. (Pubitemid 32267077)
2. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010;330:1774.
3. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ss (l-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-99. (Pubitemid 32038587)
4. Deane R, Du Yon S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-13. (Pubitemid 36889934)
5. Helmer C, Pasquier F, Dartigues JF. Épidémiologic de la maladie d'Alzheimer et des syndromes apparentés Med Set (Paris) 2006;22:288-96.
6. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6:650-61. (Pubitemid 47202487)
7. Candela P, Gosselet F, Miller F, et al. Physiological pathway for low-density lipoproteins across the blood-brain barrier: transcytosis through brain capillary endothelial cells in vitro. Endothelium 2008;15:254-64.
8. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006;112:405-15. (Pubitemid 44469161)
9. Yamada K, Hashimoto T, Yabuki C, et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem 2008;283:34554-62.
10. Ita S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier, Neurosci Res 2006;56:246-52. (Pubitemid 44572534)
11. Ito S, Ueno T, Ohtsuki S, et al. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide (l-40) in mouse: involvement of an LRP-1-independent pathway. J Neurochem 2010;113:1356-63.
12. Pflanzner T, Janko MC, Andre-Dohmen B, et al. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiot Aging 2010;12 juillet. DOI: 10.16/j. neurobiolaging.2010.05.025.
13. Eisele YS, Obermuller U, Heilbronner G, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidasis. Science 2010;330:980-2.
14. Sutcliffe JG, Hedlund PB, Thomas EA, et al. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci Res 2011;89:808-14.
15. Jeynes B, Provias J. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res 2008;5:432-7.
16. Candela P, Gosselet F, Saint-Pol J, et al. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 2010;22:849-59.
17. Sabbogh MN, Agro A, Bell J, et al. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:206-12.
18. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clm Invest 2005;115:3285-90. (Pubitemid 41567593)
19. Vogelgesang S, Warzak RW, Cascorbi I, et al. The role of P-glycoprotein in cerebral amyloid angiopathy: implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2004;1:121-5.
20. Gao W, Eisenhauer PB, Conn K, et al. Insulin degrading enzyme is expressed in the human cerebrovascular endothelium and in cultured human cerebrovascular endothelial cells. Neurosci Lett 2004;371:6-11. (Pubitemid 39410505)
21. Lynch JA, George AM, Eisenhauer PB, et al. Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures. J Neurosci Res 2006;83:1262-70. (Pubitemid 43668009)
22. Carpentier M, Robitaille Y, DesGroseillers L, et al. Declining expression of neprilysm in Alzheimer disease vasculature, possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002;61:849-56.
23. Gosselet F, Candela P, Sevin E, et al. Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. Brain Res 2009;1249:34-42.
24. Urmoneit B, Pnkulis I, Wihl G, et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lao Invest 1997;77:157-66. (Pubitemid 27355912)
25. Bell RD, Deane R, Chow N, et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 2009;11:143-53.
26. Bowman GL, Kaye JA, Moore M, et al. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 2007;68:1809-14. (Pubitemid 46791393)
27. Ujiie M, Dickstein DL, Carlow DA, et al. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003;10:463-70. (Pubitemid 39004272)
28. Tai LM, Holloway KA, Male DK, et al. Amyloid-beta-induced occludin downregulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 2010;14:1101-12.
29. Marco S, Skaper SD. Amyloid beta-peptidel-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett 2006;401:219-24. (Pubitemid 44250979)
30. Carrano A, Koozemans JJ, van der Vies SM, et al. Amyloid beta Induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy Antioxid Redox Signal 2011;15:1167-78.
31. Hémar A, Mulle C. Maladie d'Alzheimer, peptide β-amyloide et synapses. Med Set (Pans) 2011;27:733-6
32. Clovaguera F, Goedert M, Tolnay M. Induction et propagation de la pathologie par la proteine tau chez un modèle murin de la maladie d'Alzheimer. Med Sci (Paris) 2010;26:121-4.